TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07533942: A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma

Sponsor: Jazz Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$3,087,600

Rescue Site Savings

+$2,025,200

Unlock Full NCT07533942 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07533942 Rescue Dossier →